(MRAM) Everspin Technologies - Overview
Stock: MRAM, Toggle, ST-MRAM, TMR, Foundry
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 96.3% |
| Relative Tail Risk | -9.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.23 |
| Alpha | 67.92 |
| Character TTM | |
|---|---|
| Beta | 1.408 |
| Beta Downside | 1.045 |
| Drawdowns 3y | |
|---|---|
| Max DD | 57.89% |
| CAGR/Max DD | 0.27 |
Description: MRAM Everspin Technologies January 18, 2026
Everspin Technologies (NASDAQ: MRAM) designs, manufactures, and sells magnetoresistive random-access memory (MRAM) products-including Toggle MRAM, spin-transfer-torque (STT) MRAM, and tunnel-magneto-resistance sensors-through a global footprint that spans the United States, Japan, Hong Kong, Germany, Singapore, China, and Canada. Its customers span industrial, medical, automotive/transportation, aerospace, and data-center OEMs, with sales delivered via direct teams and a network of distributors and representatives.
In FY 2023 the company reported roughly $70 million in revenue and a gross margin near 55 %, reflecting the premium pricing of its non-volatile memory in safety-critical applications. The broader MRAM market is projected by independent analysts to reach ≈ $5 billion by 2027, expanding at a compound annual growth rate of ~30 %-driven primarily by automotive demand for radiation-hard, low-power memory and by data-center requirements for instant-on storage. Everspin’s cash balance of about $200 million (as of Q4 2023) provides runway for scaling its foundry partnership with TSMC’s 28 nm process and for pursuing new automotive-grade product qualifications.
Given the high-growth, technology-intensive nature of the MRAM sector, investors should monitor the pace of automotive qualification wins and the company’s ability to transition from niche OEM contracts to larger volume agreements. For a deeper quantitative view, ValueRay’s dashboard offers up-to-date financial and market metrics on MRAM.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -508.0k TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.10 > 1.0 |
| NWC/Revenue: 103.0% < 20% (prev 101.2%; Δ 1.74% < -1%) |
| CFO/TA 0.11 > 3% & CFO 9.13m > Net Income -508.0k |
| Current Ratio: 5.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.1m) vs 12m ago 5.29% < -2% |
| Gross Margin: 51.31% > 18% (prev 0.54%; Δ 5077 % > 0.5%) |
| Asset Turnover: 70.18% > 50% (prev 74.19%; Δ -4.01% > 0%) |
| Interest Coverage Ratio: -1.34 > 6 (EBITDA TTM 341.0k / Interest Expense TTM -2.06m) |
Altman Z'' -11.43
| A: 0.69 (Total Current Assets 66.6m - Total Current Liabilities 11.4m) / Total Assets 80.3m |
| B: -1.73 (Retained Earnings -138.7m / Total Assets 80.3m) |
| C: -0.04 (EBIT TTM -2.75m / Avg Total Assets 76.4m) |
| D: -9.59 (Book Value of Equity -138.6m / Total Liabilities 14.5m) |
| Altman-Z'' Score: -11.43 = D |
Beneish M 1.00
| DSRI: 0.76 (Receivables 8.69m/11.4m, Revenue 53.6m/53.9m) |
| GMI: 1.05 (GM 51.31% / 53.90%) |
| AQI: 18.03 (AQ_t 0.07 / AQ_t-1 0.00) |
| SGI: 1.00 (Revenue 53.6m / 53.9m) |
| TATA: -0.12 (NI -508.0k - CFO 9.13m) / TA 80.3m) |
| Beneish M-Score: 6.80 (Cap -4..+1) = D |
What is the price of MRAM shares?
Over the past week, the price has changed by -15.94%, over one month by -9.45%, over three months by +25.23% and over the past year by +88.28%.
Is MRAM a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MRAM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.5 | -3.8% |
| Analysts Target Price | 10.5 | -3.8% |
| ValueRay Target Price | 12.8 | 17.2% |
MRAM Fundamental Data Overview February 02, 2026
P/S = 5.535
P/B = 4.5108
P/EG = -0.6
Revenue TTM = 53.6m USD
EBIT TTM = -2.75m USD
EBITDA TTM = 341.0k USD
Long Term Debt = 3.67m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.72m USD (from shortTermDebt, last quarter)
Debt = 3.67m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -41.6m USD (from netDebt column, last quarter)
Enterprise Value = 255.3m USD (296.9m + Debt 3.67m - CCE 45.3m)
Interest Coverage Ratio = -1.34 (Ebit TTM -2.75m / Interest Expense TTM -2.06m)
EV/FCF = 61.54x (Enterprise Value 255.3m / FCF TTM 4.15m)
FCF Yield = 1.63% (FCF TTM 4.15m / Enterprise Value 255.3m)
FCF Margin = 7.73% (FCF TTM 4.15m / Revenue TTM 53.6m)
Net Margin = -0.95% (Net Income TTM -508.0k / Revenue TTM 53.6m)
Gross Margin = 51.31% ((Revenue TTM 53.6m - Cost of Revenue TTM 26.1m) / Revenue TTM)
Gross Margin QoQ = 51.25% (prev 51.27%)
Tobins Q-Ratio = 3.18 (Enterprise Value 255.3m / Total Assets 80.3m)
Interest Expense / Debt = -56.19% (Interest Expense -2.06m / Debt 3.67m)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.18m (EBIT -2.75m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.84 (Total Current Assets 66.6m / Total Current Liabilities 11.4m)
Debt / Equity = 0.06 (Debt 3.67m / totalStockholderEquity, last quarter 65.8m)
Debt / EBITDA = -122.0 (out of range, set to none) (Net Debt -41.6m / EBITDA 341.0k)
Debt / FCF = -10.02 (Net Debt -41.6m / FCF TTM 4.15m)
Total Stockholder Equity = 63.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.66% (Net Income -508.0k / Total Assets 80.3m)
RoE = -0.80% (Net Income TTM -508.0k / Total Stockholder Equity 63.9m)
RoCE = -4.08% (EBIT -2.75m / Capital Employed (Equity 63.9m + L.T.Debt 3.67m))
RoIC = -3.41% (negative operating profit) (NOPAT -2.18m / Invested Capital 63.9m)
WACC = 10.96% (E(296.9m)/V(300.6m) * Re(11.10%) + (debt cost/tax rate unavailable))
Discount Rate = 11.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.43%
[DCF Debug] Terminal Value 69.54% ; FCFF base≈3.96m ; Y1≈4.30m ; Y5≈5.35m
Fair Price DCF = 4.37 (EV 58.4m - Net Debt -41.6m = Equity 100.0m / Shares 22.9m; r=10.96% [WACC]; 5y FCF grow 9.61% → 2.90% )
EPS Correlation: -40.14 | EPS CAGR: -31.08% | SUE: -0.69 | # QB: 0
Revenue Correlation: -58.77 | Revenue CAGR: -6.68% | SUE: 0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.07 | Chg30d=+0.005 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.30 | Chg30d=-0.050 | Revisions Net=+0 | Growth EPS=+33.3% | Growth Revenue=+9.4%